Interestingly, whilst sotagliflozin showed a trend towards the lowest risk of the composite of cardiovascular death or hospitalization for HF, dapagliflozin was associated with the lowest risk of all‐cause and cardiovascular mortality. 38 With SGLT2is forming the fourth cornerstone of HF treatment, vericiguat is awaiting additional trials in patients with stable HF to potentially become the fifth cornerstone 39 in the near future as it is currently indicated in patients after a worsening HF event only.
1
—
—